Clinical trialNANot yet recruiting
Impact of Routine Electronic Patient-Reported Outcome (ePRO)Symptom Monitoring During Neoadjuvant Therapy in Patients withPancreatic Adenocarcinoma on Patient Experience and ClinicalOutcomes: A Prospective Pre-Post Implementation Study
- Outcome
- Ongoing
- Phase
- NA
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- 21 February 2027
- Expected end
- 1 July 2032
- Enrollment
- 200 participants
- Sites
- 1
- Primary outcomes
- safety and adverse events (AEs)
- Sponsor
- Other
- Results posted
- No
- Last update
- 21 September 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
To learn if routine symptom monitoring using questionnaires during chemotherapy and/or radiation therapy in patients with PDAC improves patient health-related quality of life and experience with care.
Detailed description public domain (ClinicalTrials.gov)
2.1 Primary Objectives • To determine whether implementing routine ePRO symptom monitoring during NAT in patients with PDAC improves patient health-related quality of life (HRQoL) and experience with care compared with the pre-implementation period. o To capture participant HRQoL and experience, the primary outcomes will be measured using the PROMIS-16 and CAHPS Cancer Care Survey , respectively.